Opendata, web and dolomites

VACCELERAID

A novel vaccine technology leading to accelerated availability of vaccines and improved delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VACCELERAID project word cloud

Explore the words cloud of the VACCELERAID project. It provides you a very rough idea of what is the project "VACCELERAID" about.

rna    strategy    earlier    periods    initiation    active    infectious    faster    dangerous    health    updated    technologies    introduction    regulatory    unknown    shortened    co    wishes    additional    risk    pose    accelerated    people    royalties    influenza    obtain    validating    validated    vaccination    advantage    assembly    frequently    intended    encounter    solutions    budget    lives    pasteur    competitors    gsk    fast    pharma    agreements    vaccines    milestone    manufacturing    specified    platform    model    attractiveness    consuming    gza    business    diseases    purpose    house    nucleic    ing    sudden    approval    made    demands    licensing    payments    time    capsid    receive    feasibility    area    world    start    offers    seasonal    novartis    market    global    professionals    outbreaks    companies    full    acid    proteins    sv40    markets    highlight    pandemics    met    plan    self    prepare    vaccine    public    common    marketing    delays    ip    view    sanofi    campaigns    evaluations    input    times    hereto    definitely   

Project "VACCELERAID" data sheet

The following table provides information about the project.

Coordinator
GEZA AD LTD 

Organization address
address: SIRKIN 19
city: GIVATAIYM
postcode: 53251
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GEZA AD LTD IL (GIVATAIYM) coordinator 50˙000.00

Map

 Project objective

Common to current manufacturing technologies for vaccines is the long lead-time before they were made available or novel vaccines could be made available to the public. Current methods are very time consuming and frequently encounter problems with scale-up, in particular if sudden demands have to be met. However, the ability to start vaccination campaigns fast – and earlier than currently possible – is particularly important in view of seasonal influenza, influenza pandemics or sudden outbreaks of dangerous, hereto unknown infectious diseases. Resulting delays definitely pose a high risk for health and lives of many people. To provide solutions to these world-wide challenges is of European and global interest and GZA offers such a response: The technology is based on self-assembly of SV40 capsid proteins around a given nucleic acid and has several additional applications; however, it will be validated here in the area of vaccination with RNA. The main advantage of GZA’s novel vaccine technology platform is that it enables strongly shortened manufacturing periods and accelerated market introduction of a novel vaccine (e.g., 2-3 times faster manufacturing for novel influenza vaccines). The business model is based on developing and validating the technology for a given purpose in-house and receive milestone payments and royalties specified in co-development and licensing agreements with established pharma companies active in the vaccine sector (such as GSK, Novartis or Sanofi Pasteur). Most importantly, in the feasibility assessment applied for here GZA wishes to further detail the business plan with updated evaluations of markets, competitors, IP, a project/development plan and budget to further highlight the attractiveness of the business case and to prepare initiation of a full development program in phase 2. Furthermore, it is intended to obtain input from experienced regulatory professionals and draft a potential regulatory strategy aiming at marketing approval.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACCELERAID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACCELERAID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More